What is Mesa Laboratories Inc's earnings per share (EPS)?

Mesa Laboratories Inc (MLAB) reported diluted earnings per share of $1.21 for fiscal year 2026. This represents a 436.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mesa Laboratories Inc (MLAB) Financials

MLAB

Trailing 12 months to June 30, 2026

Revenue $249.7M +3.0% YoY

Net Income $4.8M +874.2% YoY

EPS (Diluted) $0.85 +753.8% YoY

Free Cash Flow $52.9M +57.4% YoY

Market Cap $795.9M as of Oct 6, 2026

Price / Sales 3.2x on $249.7M revenue, trailing 12 months to June 30, 2026

Price / Earnings 166x on $4.8M net income, trailing 12 months to June 30, 2026

Price / Book 4.2x on $188.8M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MLAB SEC filings page.

Mesa Laboratories Inc (MLAB) reported $249.7M in revenue over the twelve months to Jun 30, 2026, up 3.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MLAB FY2026 2026-10-03

Mesa has returned to modest profitability, but its economics remain shaped by acquisition-heavy assets and uneven cash-to-earnings conversion.

The FY2024 collapse in reported earnings did not carry through to cash: operating cash flow remained positive at $44.1M while net income was a loss of $254.2M, indicating that accounting charges—not day-to-day cash generation—drove much of the damage. By FY2026, net income recovered to $6.7M, but free cash flow was $39.6M, so reported profit still understates cash produced by operations.

Gross margin expanded from 61.0% in FY2023 to 63.5% in FY2026. Operating margin recovered from 1.5% to 7.4% over the same span, showing more gross profit reached the operating line after the FY2024 disruption.

Liquidity tightened and then recovered: the current ratio fell to 0.6x in FY2025 before reaching 1.7x in FY2026. Debt-to-equity stood at 0.4x in FY2026, while goodwill represented about 44.0% of assets, so lower leverage has not made the balance sheet asset-light.

Financial Health Signals

Financial Health Score 45/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Mesa Laboratories Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Mesa Laboratories Inc has an operating margin of 7.4%, meaning the company retains $7 of operating profit per $100 of revenue. This below-average margin results in a low score of 13/100, suggesting thin profitability after operating expenses. This is up from 6.8% the prior year.

Growth

Mesa Laboratories Inc's revenue grew a modest 3.4% year-over-year to $249.1M. This slow but positive growth earns a score of 58/100.

Leverage

Mesa Laboratories Inc has a moderate D/E ratio of 0.36. This balance of debt and equity financing earns a leverage score of 48/100.

Liquidity

Mesa Laboratories Inc's current ratio of 1.72 indicates adequate short-term liquidity, earning a score of 50/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Mesa Laboratories Inc converts 15.9% of revenue into free cash flow ($39.6M). This strong cash generation earns a score of 82/100.

Returns

Mesa Laboratories Inc generates a 3.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 17/100. This is up from -1.2% the prior year.

Altman Z-Score Grey Zone

2.22

Mesa Laboratories Inc scores 2.22, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($795.9M) relative to total liabilities ($241.5M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

8/9

Mesa Laboratories Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

6.38x

For every $1 of reported earnings, Mesa Laboratories Inc generates $6.38 in operating cash flow ($42.8M OCF vs $6.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.73x

Mesa Laboratories Inc earns $1.73 in operating income for every $1 of interest expense ($18.5M vs $10.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$60.1M

YoY+1.0%

QoQ-5.6%

5Y CAGR+11.5%

10Y CAGR+11.0%

Mesa Laboratories Inc generated $60.1M in revenue in Q1 2027. This represents an increase of 1.0% from the same quarter a year earlier. Against the prior quarter it is down 5.6%.

EBITDA

$12.7M

YoY+40.5%

QoQ+49.2%

Mesa Laboratories Inc's EBITDA was $12.7M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 40.5% from the same quarter a year earlier. Against the prior quarter it is up 49.2%.

Net Income

$2.8M

YoY-40.3%

QoQ+168.4%

5Y CAGR+7.2%

10Y CAGR+3.9%

Mesa Laboratories Inc reported $2.8M in net income in Q1 2027. This represents a decrease of 40.3% from the same quarter a year earlier. Against the prior quarter it is up 168.4%.

EPS (Diluted)

$0.49

YoY-42.4%

QoQ+166.2%

5Y CAGR+5.2%

10Y CAGR-0.4%

Mesa Laboratories Inc earned $0.49 per diluted share (EPS) in Q1 2027. This represents a decrease of 42.4% from the same quarter a year earlier. Against the prior quarter it is up 166.2%.

Cash & Balance Sheet

Free Cash Flow

$14.2M

YoY+1503.7%

QoQ+4.7%

5Y CAGR+9.7%

Mesa Laboratories Inc generated $14.2M in free cash flow in Q1 2027, representing cash available after capex. This represents an increase of 1503.7% from the same quarter a year earlier. Against the prior quarter it is up 4.7%.

Cash & Debt

$30.7M

YoY+44.3%

QoQ+14.0%

5Y CAGR-35.5%

10Y CAGR+20.8%

Mesa Laboratories Inc held $30.7M in cash against $66.1M in long-term debt as of Q1 2027.

Dividends Per Share

$0.16

YoY0.0%

Mesa Laboratories Inc paid $0.16 per share in dividends in Q1 2027. That is unchanged from the same quarter a year earlier.

Shares Outstanding

YoY+1.7%

QoQ+1.3%

5Y CAGR+1.5%

10Y CAGR+4.3%

Mesa Laboratories Inc had 6M shares outstanding in Q1 2027. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.

Margins & Returns

Gross Margin

64.9%

YoY+2.8pp

QoQ-1.4pp

5Y change+1.3pp

10Y change+8.0pp

Mesa Laboratories Inc's gross margin was 64.9% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.4 percentage points.

Operating Margin

11.7%

YoY+6.5pp

QoQ+7.4pp

5Y change+2.8pp

Mesa Laboratories Inc's operating margin was 11.7% in Q1 2027, reflecting core business profitability. This is up 6.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.4 percentage points.

Net Margin

4.7%

YoY-3.3pp

QoQ+11.2pp

5Y change-1.0pp

10Y change-4.4pp

Mesa Laboratories Inc's net profit margin was 4.7% in Q1 2027, showing the share of revenue converted to profit. This is down 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.2 percentage points.

Return on Equity

1.5%

YoY-1.3pp

QoQ+3.7pp

5Y change+1.0pp

10Y change-0.7pp

Mesa Laboratories Inc's ROE was 1.5% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.

Capital Allocation

R&D Spending

$4.7M

YoY-5.2%

QoQ-9.9%

5Y CAGR+10.9%

Mesa Laboratories Inc invested $4.7M in research and development in Q1 2027. This represents a decrease of 5.2% from the same quarter a year earlier. Against the prior quarter it is down 9.9%.

Capital Expenditures

$559K

YoY-44.6%

QoQ+34.1%

5Y CAGR-3.1%

Mesa Laboratories Inc invested $559K in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 44.6% from the same quarter a year earlier. Against the prior quarter it is up 34.1%.

Share Buybacks

Not reported for Q1 2027.

MLAB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MLAB quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$249.7M	$249.1M+3.4%	$241.0M+11.5%	$216.2M-1.3%	$219.1M+18.8%	$184.3M+37.6%	$133.9M+13.8%	$117.7M+14.1%	$103.1M+7.2%	$96.2M+2.7%	$93.7M+10.6%	$84.7M+18.7%	$71.3M+35.3%	$52.7M+13.5%	$46.4M+17.2%	$39.6M
Cost of Revenue	$89.4M	$90.9M+0.8%	$90.1M+8.6%	$82.9M-2.9%	$85.4M+13.5%	$75.2M+60.4%	$46.9M-10.3%	$52.3M+23.9%	$42.2M+1.6%	$41.6M+2.8%	$40.4M+21.6%	$33.2M+19.0%	$27.9M+32.8%	$21.0M+19.7%	$17.6M+9.1%	$16.1M
Gross Profit	$160.3M	$158.3M+4.9%	$150.9M+13.2%	$133.3M-0.3%	$133.7M+22.6%	$109.1M+25.4%	$87.0M+33.1%	$65.4M+7.3%	$60.9M+11.5%	$54.6M+2.6%	$53.2M+3.6%	$51.4M+18.5%	$43.4M+36.9%	$31.7M+9.8%	$28.9M+22.8%	$23.5M
R&D Expenses	$20.0M	$20.3M+4.0%	$19.5M+1.1%	$19.3M-5.8%	$20.5M+30.0%	$15.8M+51.8%	$10.4M+63.5%	$6.4M+81.3%	$3.5M-0.9%	$3.5M-14.9%	$4.2M+4.7%	$4.0M+20.6%	$3.3M+42.0%	$2.3M+15.4%	$2.0M+48.0%	$1.4M
SG&A Expenses	$78.1M	$78.7M+7.3%	$73.3M+0.6%	$72.9M+0.6%	$72.4M+20.1%	$60.3M+31.7%	$45.8M+19.9%	$38.2M+22.0%	$31.3M+19.2%	$26.3M+15.1%	$22.8M-3.4%	$23.6M+38.5%	$17.1M+48.8%	$11.5M+25.7%	$9.1M+68.3%	$5.4M
Operating Income	$22.5M	$18.5M+13.3%	$16.3M+106.0%	-$272.1M-8295.0%	$3.3M-29.4%	$4.7M-62.0%	$12.4M+56.0%	$7.9M-19.0%	$9.8M+348.1%	$2.2M-86.6%	$16.3M-0.1%	$16.3M+2.9%	$15.9M+34.6%	$11.8M-10.1%	$13.1M+5.0%	$12.5M
EBITDA	N/A	$41.8M+2.2%	$40.9M+117.0%	-$240.5M-747.5%	$37.1M+24.8%	$29.8M-0.8%	$30.0M+43.5%	$20.9M+8.9%	$19.2M+64.8%	$11.7M-53.5%	$25.1M+6.6%	$23.5M+9.2%	$21.5M+37.7%	$15.6M-5.5%	$16.5M+12.6%	$14.7M
Interest Expense	$10.9M	$10.7M-9.8%	$11.9M+108.2%	$5.7M+19.4%	$4.8M+22.8%	$3.9M-51.6%	$8.0M+45.8%	$5.5M+214.7%	$1.7M-5.6%	$1.9M	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$4.6M	$5.3M-33.2%	$7.9M+137.1%	-$21.4M-1522.6%	-$1.3M-177.5%	$1.7M+275.4%	-$971K-146.6%	$2.1M+83.0%	$1.1M-65.1%	$3.3M+4.8%	$3.1M-29.0%	$4.4M-23.9%	$5.8M+40.5%	$4.1M-9.4%	$4.5M+2.6%	$4.4M
Net Income	$4.8M	$6.7M+440.0%	-$2.0M+99.2%	-$254.2M-27438.3%	$930K-50.3%	$1.9M-42.9%	$3.3M+84.1%	$1.8M-76.2%	$7.5M+352.7%	-$3.0M-126.5%	$11.2M+0.1%	$11.2M+16.6%	$9.6M+6.5%	$9.0M+6.5%	$8.4M+6.7%	$7.9M
EPS (Basic)	N/A	$1.22+438.9%	-$0.36+99.2%	-$47.20-27864.7%	$0.17-52.8%	$0.36-45.5%	$0.66+57.1%	$0.42-78.5%	$1.95+346.8%	-$0.79-126.0%	$3.04-1.9%	$3.10+14.0%	$2.72+4.2%	$2.61+3.6%	$2.52+4.6%	$2.41
EPS (Diluted)	$0.85	$1.21+436.1%	-$0.36+99.2%	-$47.20-27864.7%	$0.17-51.4%	$0.35-45.3%	$0.64+56.1%	$0.41-78.0%	$1.86+335.4%	-$0.79-127.1%	$2.91-2.0%	$2.97+12.9%	$2.63+5.6%	$2.49+6.0%	$2.35+2.6%	$2.29
Diluted Shares (Avg)	N/A	6M+2.7%	5M+0.6%	5M+0.5%	5M+0.5%	5M+4.1%	5M+17.2%	4M+8.4%	4M+7.0%	4M-1.9%	4M+2.3%	4M+2.9%	4M+1.1%	4M+0.5%	4M+3.8%	3M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$60.1M+1.0%	$63.7M+2.6%	$65.1M+3.6%	$60.7M+5.0%	$59.5M+2.4%	$62.1M+5.5%	$62.8M+17.5%	$57.8M+8.8%
Cost of Revenue	$21.1M-6.5%	$21.5M-9.3%	$23.3M+1.1%	$23.4M+4.6%	$22.6M+8.0%	$23.7M+6.2%	$23.1M+15.0%	$22.4M+6.3%
Gross Profit	$39.0M+5.6%	$42.2M+9.9%	$41.8M+5.1%	$37.3M+5.3%	$36.9M-0.8%	$38.4M+5.1%	$39.8M+19.0%	$35.5M+10.4%
R&D Expenses	$4.7M-5.2%	$5.2M+3.0%	$5.0M-0.5%	$5.0M+8.9%	$5.0M+5.3%	$5.1M-2.0%	$5.1M+17.7%	$4.6M-7.2%
SG&A Expenses	$17.4M-3.2%	$24.1M+17.3%	$18.8M+1.8%	$17.8M+1.7%	$18.0M+6.8%	$20.6M+15.3%	$18.5M-5.0%	$17.5M-0.4%
Operating Income	$7.0M+129.5%	$2.7M+87.1%	$8.0M+38.0%	$4.7M+34.7%	$3.1M-45.1%	$1.5M+100.5%	$5.8M+8725.4%	$3.5M+5946.7%
EBITDA	$12.7M+40.5%	$8.5M-5.2%	$13.7M+21.4%	$10.6M+10.4%	$9.0M-18.3%	$9.0M+103.4%	$11.3M+25.5%	$9.6M+19.2%
Interest Expense	$2.4M+7.5%	$2.6M-17.8%	$3.0M+6.8%	$2.9M-5.2%	$2.2M-22.7%	$3.2M+67.2%	$2.8M+53.1%	$3.0M+233.5%
Income Tax	$1.5M-32.9%	$2.5M-66.4%	$966K+278.6%	-$477K-224.2%	$2.3M+339.1%	$7.6M+136.5%	-$541K-218.2%	$384K+504.2%
Net Income	$2.8M-40.3%	-$4.1M+41.9%	$3.6M+316.6%	$2.5M-27.8%	$4.7M+40.0%	-$7.1M+97.2%	-$1.7M-179.2%	$3.4M+378.7%
EPS (Basic)	$0.50-42.5%	-$0.75+42.7%	$0.66+312.9%	$0.45-28.6%	$0.87+38.1%	-$1.31+97.2%	-$0.31-179.5%	$0.63+373.9%
EPS (Diluted)	$0.49-42.4%	-$0.74+43.1%	$0.65+309.7%	$0.45-28.6%	$0.85+37.1%	-$1.30+97.2%	-$0.31-179.5%	$0.63+373.9%
Diluted Shares (Avg)	6M+3.7%	N/A	6M+2.5%	6M+1.2%	6M+2.4%	N/A	5M+0.6%	5M+1.6%

MLAB Balance Sheet

MLAB quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$427.7M-1.3%	$433.3M-3.0%	$446.8M-32.5%	$661.8M-6.4%	$707.4M+17.6%	$601.5M+47.0%	$409.1M+161.0%	$156.8M-4.5%	$164.1M-4.4%	$171.7M+6.8%	$160.7M+37.0%	$117.3M+20.3%	$97.5M0.0%	$97.5M+92.4%	$50.7M
Current Assets	$106.3M+3.5%	$102.7M-6.1%	$109.4M-8.1%	$119.0M-4.3%	$124.3M-59.1%	$303.7M+147.4%	$122.8M+265.2%	$33.6M+5.1%	$32.0M-10.6%	$35.8M-3.8%	$37.2M+25.5%	$29.6M+11.5%	$26.6M+36.6%	$19.5M+1.5%	$19.2M
Cash & Equivalents	$26.9M-1.4%	$27.3M-3.2%	$28.2M-14.3%	$32.9M-33.3%	$49.3M-81.3%	$263.9M+224.2%	$81.4M+699.0%	$10.2M+86.2%	$5.5M-6.0%	$5.8M+2.2%	$5.7M+180.0%	$2.0M-63.5%	$5.6M+39.2%	$4.0M-44.3%	$7.2M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$26.4M+4.0%	$25.4M-22.4%	$32.7M-5.7%	$34.6M+40.8%	$24.6M+120.1%	$11.2M0.0%	$11.2M+65.1%	$6.8M-26.6%	$9.2M-33.5%	$13.9M-1.0%	$14.0M+12.9%	$12.4M+59.8%	$7.8M+39.4%	$5.6M+25.6%	$4.4M
Accounts Receivable	$44.1M+5.1%	$42.0M+7.5%	$39.1M-8.2%	$42.6M+3.2%	$41.2M+73.3%	$23.8M+12.6%	$21.1M+68.8%	$12.5M-12.5%	$14.3M-0.1%	$14.3M-6.5%	$15.3M+26.1%	$12.1M+30.9%	$9.3M+9.5%	$8.5M+30.7%	$6.5M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$186.9M+2.8%	$181.8M+0.9%	$180.1M-37.1%	$286.4M-1.6%	$291.2M+81.0%	$160.8M+13.6%	$141.5M+113.2%	$66.4M+1.3%	$65.5M-9.2%	$72.2M+9.1%	$66.1M+47.4%	$44.9M+18.5%	$37.9M+60.2%	$23.6M+63.6%	$14.4M
Total Liabilities	$241.5M-11.7%	$273.5M-9.3%	$301.4M+12.3%	$268.4M-14.4%	$313.6M+60.6%	$195.2M+3.3%	$189.1M+316.0%	$45.5M-29.8%	$64.7M-12.4%	$73.9M-2.8%	$76.1M+73.5%	$43.8M+32.1%	$33.2M-25.9%	$44.8M+560.3%	$6.8M
Current Liabilities	$61.9M-62.2%	$164.0M+270.0%	$44.3M+2.2%	$43.4M-9.8%	$48.1M+47.5%	$32.6M+25.3%	$26.0M+9.9%	$23.7M+36.8%	$17.3M+4.4%	$16.6M-30.9%	$24.0M+63.5%	$14.7M+43.5%	$10.2M+119.1%	$4.7M+9.4%	$4.3M
Non-Current Liabilities	$179.6M+63.9%	$109.6M-57.4%	$257.1M+14.3%	$225.0M-15.3%	$265.5M+63.2%	$162.7M-0.3%	$163.1M+648.3%	$21.8M-54.1%	$47.5M-17.3%	$57.3M+10.1%	$52.1M+78.5%	$29.2M+27.0%	$23.0M-42.7%	$40.1M+1492.5%	$2.5M
Long-Term Debt	$67.5M-5.3%	$71.3M	N/A	N/A	N/A	N/A	N/A	$20.6M-53.8%	$44.6M-16.8%	$53.7M+27.0%	$42.3M+81.7%	$23.3M+40.9%	$16.5M+312.5%	$4.0M	N/A
Total Equity	$186.2M+16.5%	$159.8M+9.9%	$145.4M-63.0%	$393.5M-0.1%	$393.8M-3.1%	$406.2M+84.6%	$220.0M+97.7%	$111.3M+12.0%	$99.4M+1.6%	$97.8M+15.5%	$84.7M+15.2%	$73.5M+14.2%	$64.3M+22.0%	$52.8M+20.1%	$43.9M
Retained Earnings	-$185.7M+1.7%	-$188.9M-3.0%	-$183.5M-347.3%	$74.2M-3.2%	$76.7M+5.8%	$72.5M+0.1%	$72.4M-1.3%	$73.3M+7.4%	$68.3M-7.3%	$73.7M+13.6%	$64.8M+15.8%	$56.0M+15.2%	$48.6M+16.9%	$41.5M+16.2%	$35.7M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$419.2M-3.8%	$427.7M-1.3%	$434.8M+0.3%	$430.4M-5.2%	$435.7M-1.0%	$433.3M-3.0%	$433.3M-41.6%	$454.1M-28.7%
Current Assets	$102.8M+4.7%	$106.3M+3.5%	$105.6M+2.9%	$97.4M-9.8%	$98.3M-7.9%	$102.7M-6.1%	$102.7M-13.2%	$108.0M-8.2%
Cash & Equivalents	$30.7M+44.3%	$26.9M-1.4%	$29.0M+6.1%	$20.4M-16.1%	$21.3M-25.3%	$27.3M-3.2%	$27.3M-3.2%	$24.3M-31.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$27.2M-3.1%	$26.4M+4.0%	$26.6M+4.7%	$27.7M-6.7%	$28.1M-11.5%	$25.4M-22.4%	$25.4M-29.5%	$29.7M-9.6%
Accounts Receivable	$34.4M-11.9%	$44.1M+5.1%	$40.2M-4.1%	$40.1M-0.4%	$39.1M+9.8%	$42.0M+7.5%	$42.0M+16.5%	$40.2M+10.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$186.0M-1.1%	$186.9M+2.8%	$189.3M+4.1%	$188.5M+2.6%	$188.1M+4.6%	$181.8M+0.9%	$181.8M-47.5%	$183.8M-35.1%
Total Liabilities	$230.5M-12.5%	$241.5M-11.7%	$248.2M-9.3%	$251.9M-13.9%	$263.2M-9.1%	$273.5M-9.3%	$273.5M-19.3%	$292.6M+17.3%
Current Liabilities	$57.3M-61.7%	$61.9M-62.2%	$54.4M-66.8%	$48.3M-68.5%	$149.5M+172.5%	$164.0M+270.0%	$164.0M+271.1%	$153.2M+284.8%
Non-Current Liabilities	$173.1M+52.2%	$179.6M+63.9%	$193.8M+76.9%	$203.6M+46.0%	$113.8M-51.5%	$109.6M-57.4%	$109.6M-62.8%	$139.4M-33.5%
Long-Term Debt	$66.1M-6.0%	$67.5M-5.3%	$68.4M-5.2%	$69.4M-5.1%	$70.3M-5.1%	$71.3M	$72.2M	$73.1M
Total Equity	$188.8M+9.4%	$186.2M+16.5%	$186.7M+20.3%	$178.5M+10.5%	$172.5M+14.4%	$159.8M+9.9%	$155.2M-61.5%	$161.5M-58.4%
Retained Earnings	-$183.8M+0.7%	-$185.7M+1.7%	-$180.7M+4.3%	-$183.5M-2.8%	-$185.1M-2.3%	-$188.9M-3.0%	-$188.9M-362.6%	-$178.4M-352.3%

MLAB Cash Flow Statement

MLAB quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$55.7M	$42.8M-8.5%	$46.8M+6.1%	$44.1M+57.7%	$28.0M-28.7%	$39.2M+5.8%	$37.1M+37.4%	$27.0M-11.7%	$30.6M+18.8%	$25.7M+48.6%	$17.3M+2.4%	$16.9M+56.3%	$10.8M-12.6%	$12.4M+8.5%	$11.4M-8.7%	$12.5M
Depreciation & Amortization	N/A	$23.3M-5.1%	$24.5M-22.3%	$31.6M-6.7%	$33.8M+34.9%	$25.1M+41.9%	$17.7M+36.0%	$13.0M+37.8%	$9.4M-0.5%	$9.5M+8.4%	$8.7M+21.8%	$7.2M+26.8%	$5.7M+47.1%	$3.8M+12.0%	$3.4M+54.9%	$2.2M
Stock-Based Compensation	N/A	$17.9M+36.0%	$13.1M+10.1%	$11.9M-4.8%	$12.5M+10.1%	$11.4M+22.9%	$9.3M+67.7%	$5.5M+31.2%	$4.2M+151.9%	$1.7M+18.5%	$1.4M+6.3%	$1.3M+33.6%	$993K+18.2%	$840K-24.5%	$1.1M+139.7%	$464K
Capital Expenditures	$2.8M	$3.3M-23.5%	$4.2M+65.5%	$2.6M-43.5%	$4.5M+2.5%	$4.4M+122.5%	$2.0M+33.0%	$1.5M+18.7%	$1.3M-54.9%	$2.8M	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	$52.9M	$39.6M-7.0%	$42.6M+2.4%	$41.6M+77.3%	$23.4M-32.6%	$34.8M-0.8%	$35.1M+37.6%	$25.5M-13.0%	$29.3M+27.8%	$22.9M	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$2.8M	-$3.3M+27.8%	-$4.5M+94.5%	-$81.3M-756.4%	-$9.5M+96.9%	-$305.2M-15222.5%	-$2.0M+98.9%	-$185.6M-4683.1%	-$3.9M+77.4%	-$17.2M+6.6%	-$18.4M+42.2%	-$31.8M	N/A	N/A	N/A	N/A
Financing Cash Flow	-$43.9M	-$41.9M+6.0%	-$44.5M-235.5%	$32.8M+198.5%	-$33.3M-163.4%	$52.6M-64.0%	$146.2M-36.8%	$231.3M+1167.2%	-$21.7M-140.2%	-$9.0M-882.0%	$1.2M-93.8%	$18.6M	N/A	N/A	N/A	N/A
Dividends Paid	$3.5M	$3.5M+1.6%	$3.5M+0.6%	$3.4M+1.2%	$3.4M+2.0%	$3.3M+5.5%	$3.2M+16.3%	$2.7M+10.6%	$2.5M+2.0%	$2.4M+2.5%	$2.4M+2.3%	$2.3M+5.5%	$2.2M+9.7%	$2.0M+9.6%	$1.8M+10.3%	$1.6M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$22K-78.4%	$102K-82.9%	$597K

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	$14.7M+678.4%	$14.0M+10.2%	$18.8M+3.4%	$8.2M+56.0%	$1.9M-82.4%	$12.7M-1.7%	$18.1M+57.2%	$5.3M-46.1%
Depreciation & Amortization	$5.6M-5.2%	$5.8M-23.3%	$5.7M+4.0%	$5.8M-3.6%	$6.0M+9.0%	$7.5M+19.1%	$5.5M-39.3%	$6.1M-25.0%
Stock-Based Compensation	$2.4M-39.2%	N/A	N/A	N/A	$3.9M+32.5%	N/A	N/A	N/A
Capital Expenditures	$559K-44.6%	$417K-44.9%	$732K-10.0%	$1.1M-38.9%	$1.0M+13.2%	$757K+41.5%	$813K-27.9%	$1.8M+182.0%
Free Cash Flow	$14.2M+1503.7%	$13.5M+13.7%	$18.0M+4.1%	$7.1M+104.7%	$884K-91.0%	$11.9M-3.6%	$17.3M+66.4%	$3.5M-61.9%
Investing Cash Flow	-$559K+44.6%	-$417K+58.6%	-$732K+10.0%	-$1.1M+38.9%	-$1.0M-13.2%	-$1.0M-336.4%	-$813K+99.0%	-$1.8M-182.0%
Financing Cash Flow	-$10.5M-24.6%	-$15.8M+2.7%	-$9.8M+4.9%	-$7.9M+8.4%	-$8.4M+10.5%	-$16.2M-25.2%	-$10.3M-116.9%	-$8.6M-54.9%
Dividends Paid	$884K+1.3%	$884K+1.6%	$884K+1.7%	$882K+1.8%	$873K+1.2%	$870K+0.7%	$869K+0.8%	$866K+0.5%

Not reported in any period shown, so not listed: Share Buybacks.

MLAB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MLAB quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	63.5%+0.9pp	62.6%+1.0pp	61.6%+0.6pp	61.0%+1.8pp	59.2%-5.8pp	65.0%+9.4pp	55.5%-3.5pp	59.1%+2.3pp	56.8%-0.1pp	56.8%-3.9pp	60.7%-0.1pp	60.8%+0.7pp	60.1%-2.1pp	62.2%+2.8pp	59.4%
Operating Margin	7.4%+0.7pp	6.8%	-125.8%	1.5%-1.0pp	2.5%-6.7pp	9.2%+2.5pp	6.7%-2.7pp	9.5%+7.2pp	2.3%-15.2pp	17.4%-1.9pp	19.3%-3.0pp	22.2%-0.1pp	22.4%-5.9pp	28.2%-3.3pp	31.5%
Net Margin	2.7%+3.5pp	-0.8%	-117.6%	0.4%-0.6pp	1.0%-1.4pp	2.4%+0.9pp	1.5%-5.8pp	7.3%+10.3pp	-3.1%-15.0pp	11.9%-1.2pp	13.2%-0.2pp	13.4%-3.6pp	17.1%-1.1pp	18.2%-1.8pp	20.0%
Return on Equity	3.6%+4.8pp	-1.2%+173.6pp	-174.9%-175.1pp	0.2%-0.2pp	0.5%-0.3pp	0.8%0.0pp	0.8%-5.9pp	6.7%+9.7pp	-3.0%-14.4pp	11.4%-1.8pp	13.2%+0.2pp	13.0%-1.0pp	14.0%-2.0pp	16.0%-2.0pp	18.0%
Return on Assets	1.6%+2.0pp	-0.5%+56.4pp	-56.9%-57.0pp	0.1%-0.1pp	0.3%-0.3pp	0.5%+0.1pp	0.4%-4.3pp	4.8%+6.6pp	-1.8%-8.3pp	6.5%-0.4pp	7.0%-1.2pp	8.2%-1.1pp	9.2%+0.6pp	8.7%-7.0pp	15.6%
Current Ratio	1.72+1.1x	0.63-1.8x	2.47-0.3x	2.74+0.2x	2.59-6.7x	9.32+4.6x	4.72+3.3x	1.42-0.4x	1.85-0.3x	2.16+0.6x	1.55-0.5x	2.02-0.6x	2.60-1.6x	4.17-0.3x	4.50
Debt-to-Equity	0.36-0.1x	0.45-1.6x	2.07+1.4x	0.68-0.1x	0.80+0.3x	0.48-0.4x	0.86+0.7x	0.19-0.3x	0.45-0.1x	0.550.0x	0.50+0.2x	0.32+0.1x	0.26+0.2x	0.08-0.1x	0.15
Asset Turnover	0.580.0x	0.56+0.1x	0.48+0.2x	0.33+0.1x	0.260.0x	0.22-0.1x	0.29-0.4x	0.66+0.1x	0.590.0x	0.550.0x	0.53-0.1x	0.61+0.1x	0.54+0.1x	0.48-0.3x	0.78
FCF Margin	15.9%-1.8pp	17.7%-1.6pp	19.2%+8.5pp	10.7%-8.2pp	18.9%-7.3pp	26.2%+4.5pp	21.7%-6.7pp	28.4%+4.6pp	23.8%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	64.9%+2.8pp	66.2%+4.4pp	64.2%+0.9pp	61.5%+0.2pp	62.0%-2.0pp	61.8%-0.2pp	63.3%+0.8pp	61.3%+0.9pp
Operating Margin	11.7%+6.5pp	4.3%+1.9pp	12.3%+3.0pp	7.8%+1.7pp	5.1%-4.4pp	2.4%	9.2%+9.3pp	6.1%+6.2pp
Net Margin	4.7%-3.3pp	-6.5%+5.0pp	5.6%+8.2pp	4.1%-1.8pp	8.0%+2.1pp	-11.5%	-2.7%-6.6pp	5.9%+8.2pp
Return on Equity	1.5%-1.3pp	-2.2%+2.2pp	1.9%+3.0pp	1.4%-0.7pp	2.8%+0.5pp	-4.5%+170.6pp	-1.1%-1.6pp	2.1%+2.4pp
Return on Assets	0.7%-0.4pp	-1.0%+0.7pp	0.8%+1.2pp	0.6%-0.2pp	1.1%+0.3pp	-1.6%+55.3pp	-0.4%-0.7pp	0.8%+0.9pp
Current Ratio	1.79+1.1x	1.72+1.1x	1.94+1.3x	2.02+1.3x	0.66-1.3x	0.63-1.8x	0.63-2.1x	0.70-2.3x
Debt-to-Equity	0.35-0.1x	0.36-0.1x	0.37-0.1x	0.39-0.1x	0.41-0.1x	0.45-1.6x	0.47-0.4x	0.45-0.2x
Asset Turnover	0.140.0x	0.150.0x	0.150.0x	0.140.0x	0.140.0x	0.140.0x	0.14+0.1x	0.130.0x
FCF Margin	23.6%+22.1pp	21.3%+2.1pp	27.7%+0.1pp	11.7%+5.7pp	1.5%-15.5pp	19.2%-1.8pp	27.6%+8.1pp	6.0%-11.2pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Mesa Laboratories Inc MLAB	FY2026	$249.1M	$6.7M	2.7%	$795.9M	45/100
Vishay Precision Group, Inc. VPG	FY2025	$307.2M	$5.3M	1.7%	$1.1B	58/100
Microvision Inc MVIS	FY2025	$1.2M	-$95.0M	N/A	$45.3M	44/100
Ituran Location and Control Ltd. ITRN	FY2025	$359.0M	$58.0M	16.2%	$1.0B	74/100

Where Mesa Laboratories Inc Ranks

Frequently Asked Questions

What is Mesa Laboratories Inc's annual revenue?

Mesa Laboratories Inc (MLAB) reported $249.1M in total revenue for fiscal year 2026. This represents a 3.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Mesa Laboratories Inc's revenue growing?

Mesa Laboratories Inc (MLAB) revenue grew by 3.4% year-over-year, from $241.0M to $249.1M in fiscal year 2026.

Is Mesa Laboratories Inc profitable?

Yes, Mesa Laboratories Inc (MLAB) reported a net income of $6.7M in fiscal year 2026, with a net profit margin of 2.7%.

What is Mesa Laboratories Inc's EBITDA?

Mesa Laboratories Inc (MLAB) had EBITDA of $41.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Mesa Laboratories Inc have?

As of fiscal year 2026, Mesa Laboratories Inc (MLAB) had $26.9M in cash and equivalents against $67.5M in long-term debt.

What is Mesa Laboratories Inc's gross margin?

Mesa Laboratories Inc (MLAB) had a gross margin of 63.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Mesa Laboratories Inc's operating margin?

Mesa Laboratories Inc (MLAB) had an operating margin of 7.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Mesa Laboratories Inc's net profit margin?

Mesa Laboratories Inc (MLAB) had a net profit margin of 2.7% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Does Mesa Laboratories Inc pay dividends?

Yes, Mesa Laboratories Inc (MLAB) paid $0.64 per share in dividends during fiscal year 2026.

What is Mesa Laboratories Inc's return on equity (ROE)?

Mesa Laboratories Inc (MLAB) has a return on equity of 3.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Mesa Laboratories Inc's free cash flow?

Mesa Laboratories Inc (MLAB) generated $39.6M in free cash flow during fiscal year 2026. This represents a -7.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Mesa Laboratories Inc's operating cash flow?

Mesa Laboratories Inc (MLAB) generated $42.8M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Mesa Laboratories Inc's total assets?

Mesa Laboratories Inc (MLAB) had $427.7M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Mesa Laboratories Inc's capital expenditures?

Mesa Laboratories Inc (MLAB) invested $3.3M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Mesa Laboratories Inc spend on research and development?

Mesa Laboratories Inc (MLAB) invested $20.3M in research and development during fiscal year 2026.

How many shares does Mesa Laboratories Inc have outstanding?

Mesa Laboratories Inc (MLAB) had 6M shares outstanding as of fiscal year 2026.

What is Mesa Laboratories Inc's current ratio?

Mesa Laboratories Inc (MLAB) had a current ratio of 1.72 as of fiscal year 2026, which is generally considered healthy.

What is Mesa Laboratories Inc's debt-to-equity ratio?

Mesa Laboratories Inc (MLAB) had a debt-to-equity ratio of 0.36 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Mesa Laboratories Inc's return on assets (ROA)?

Mesa Laboratories Inc (MLAB) had a return on assets of 1.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Mesa Laboratories Inc's P/E ratio?

Mesa Laboratories Inc (MLAB) trades at 166x earnings, its market capitalization divided by net income of $4.8M net income, trailing 12 months to June 30, 2026. The market capitalization is $795.9M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Mesa Laboratories Inc's price-to-sales ratio?

Mesa Laboratories Inc (MLAB) trades at 3.2x sales, its market capitalization divided by revenue of $249.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $795.9M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Mesa Laboratories Inc's Altman Z-Score?

Mesa Laboratories Inc (MLAB) has an Altman Z-Score of 2.22, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Mesa Laboratories Inc's Piotroski F-Score?

Mesa Laboratories Inc (MLAB) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Mesa Laboratories Inc's earnings high quality?

Mesa Laboratories Inc (MLAB) has an earnings quality ratio of 6.38x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Mesa Laboratories Inc cover its interest payments?

Mesa Laboratories Inc (MLAB) has an interest coverage ratio of 1.73x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Mesa Laboratories Inc?

Mesa Laboratories Inc (MLAB) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.